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Abstract The aim of the study is to evaluate the preva-
lence and incidence of myocardial dysfunction (MD) and
heart failure (HF) in long-lasting (C10 years) type 1 dia-
betes without cardiovascular disorders or with hypertension
or coronary heart disease (CHD). The study included 1,685
patients with type 1 diabetes (mean baseline age, 51 years;
diabetes duration, 36 years). In all patients, echocardiog-
raphy was performed, NT-proBNP levels were measured,
and clinical symptoms were evaluated. A 7-year follow-up
was conducted to monitor systolic and diastolic manifes-
tations of MD and HF. At the end of the follow-up period,
the prevalence of HF in the entire group was 3.7 %, and the
incidence was 0.02 % per year. The prevalence of MD was
14.5 % and the incidence –0.1 % per year. MD and HF
were observed only in hypertensive or CHD patients. At
baseline, subjects with diastolic HF constituted 85 % of the
HF population and those with systolic HF the remaining
15 %. Baseline HF predictors included age, diabetes
duration, HbA1c levels, CHD, systolic blood pressure
[140 mmHg, and GFR \60 mL/min/1.73 m2. In patients
with type 1 diabetes, MD and HF occurred only when
diabetes coexisted with cardiovascular disorders affecting
myocardial function. The prevalence and incidence of HF
in patients with hypertension and CHD were relatively low.
While the cause of this observation remains uncertain, it
could probably be explained, at least partially, by the
cardioprotective effect of concomitant treatment.
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Abbreviations
A Peak velocity of late left ventricular
diastolic filling
A0 Late diastolic velocity at lateral mitral
annulus
Ar Pulmonary venous atrial reversal velocity
CHD Coronary heart disease
DC Diabetic cardiomyopathy
DT E-wave deceleration time
E Peak velocity of early left ventricular
diastolic filling
E/A Ratio of early and late left ventricular
diastolic filling
E/E0 Ratio of E and E0
E0 Early diastolic velocity at lateral mitral
annulus
HFPEF Heart failure with preserved left ventricular
ejection fraction
HFREF Heart failure with reduced left ventricular
ejection fraction
HbA1c Glycosylated haemoglobin
LAVI Left atrial volume index
LVDF Left ventricular diastolic filling
LVEF Left ventricular ejection fraction
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Introduction
The prevalence of heart failure (HF) in the general popu-
lation is estimated at 1–4 %, depending on the age group.
According to the epidemiological studies, from 12 to 22 %
of diabetic patients suffer from HF [1–9].
A number of independent risk factors for the develop-
ment of HF have been identified in patients with diabetes.
Apart from metabolic disturbances related to hyperglyca-
emia, the two most common risk factors for the develop-
ment of HF are coronary heart disease (CHD) and
hypertension, which are more prevalent in patients with
diabetes than in the general population [1–10].
Myocardial dysfunction (MD) is a clinically asymp-
tomatic state, which may precede or coexist with HF
symptoms. Early diagnosis of MD is vitally important
because specific therapy applied at this stage can effec-
tively delay the actual onset of HF. However, the preva-
lence of MD and HF in diabetic patients has not been
extensively studied. The majority of studies to date have
focused only on type 2 diabetes or did not distinguish
between type 1 and type 2 diabetes. Moreover, they did not
differentiate between systolic and diastolic manifestations
of MD and HF [1–10].
Determining the effect of metabolic disturbances asso-
ciated with type 1 diabetes on cardiac function still remains
a challenge in the era of modern intensive insulin therapy.
The potential effect of hypertension and CHD on the
prevalence of MD and HF in type 1 diabetes also requires
further investigation.
The aim of the current study was to examine the preva-
lence and incidence of MD and HF in long-lasting (C10
years) type 1 diabetes without cardiovascular comorbidities
or with concomitant hypertension and CHD.
Methods
Our research was designed as a prospective cohort study.
Cohort
We identified a cohort from the registries of diabetes
clinics in 5 Polish counties and of the Department of
Metabolic Diseases at the Jagiellonian University School
of Medicine, Krakow, which is a reference centre for dia-
betes care in south-eastern Poland. We also had access to
the medical records of all hospitalized diabetic patients in
the above facilities. All 1,856 subjects were recruited
between 1999 and 2004. The cohort included consecutive
patients that had been diagnosed at the Department of
Coronary Disease at the Jagiellonian University. It corre-
sponds to the number of type 1 diabetic patients who
agreed to participate in the study during that period.
Inclusion criteria
1. Patients over 18 years of age with type 1 diabetes
(insulin therapy from the beginning of the disease;
diabetes diagnosed before the age of 30),
2. Diabetes duration C10 years.
Exclusion criteria (129 individuals excluded)
1. Comorbidities other than hypertension and CHD that
can affect myocardial function: pulmonary disorders
with dyspnoea (n = 53), severe rheumatic valve dis-
eases (n = 42), a history of myocarditis (n = 10),
systemic diseases with cardiac involvement (n = 4)
2. Difficulty in assessing diastolic function (permanent
atrial fibrillation, cardiac pacemaker); n = 10
3. Refusal to give informed consent (n = 10).
Clinical examination
All participants underwent baseline subjective and objec-
tive clinical examination. Hypertension was defined as
C140/90 mmHg (at least on two separate measurements)
or hypotensive therapy initiated due to elevated blood
pressure. Cardiac autonomic neuropathy (CAN) was diag-
nosed according to the applicable standards [11, 12].
Laboratory measurements
Baseline serum N-terminal pro-B-type natriuretic peptide
(NT-proBNP) levels were determined with an electro-
chemiluminescence assay (Elecsys, Roche Diagnostic,
France) in one central laboratory. The normal value for
healthy individuals aged\75 years was\125 pg/ml. Other
biochemical tests were also performed as presented in
Tables 1, 2, 3.
Echocardiography
Complete echocardiography was performed using the
Simens Sequoia C 512 ECHO unit equipped with a multi-
frequency, harmonic transducer (2.5–4 MHz). The average
values of three consecutive measurements were recorded.
All patients were examined by the same operator.
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HF with preserved left ventricular (LV) ejection fraction
(EF) (HFPEF) or diastolic heart failure was defined as the
presence of:
1. Signs or symptoms of HF
2. Normal or mildly abnormal LV systolic function
(EF C 50 %)
3. Evidence of LV diastolic dysfunction.
All three criteria had to be met to diagnose HFPEF [13,
14]Heart failure with reduced LVEF (HFREF) was defined
as the presence of:
1. Signs or symptoms of HF
2. Evidence of LV systolic dysfunction.
Both criteria had to be met to diagnose HFREF [13, 14].
Diastolic LV dysfunction was diagnosed when: [14]
(a) E/E0[ 15 or
(b) 8 \ E/E0\ 15 and the serum level of NT-proB-
NP [ 220 pg/ml or
(c) 8 \ E/E0\ 15 and any of the following criteria:
E/A \ 1.0 and DT [ 200 ms \ 50 years
E/A \ 0.5 and DT [ 280 ms [ 50 years (impaired
relaxation)
E/A = (1.0–2.0)
and at least two (jointly) of the following criteria:
S/D\1 or Ar C 35 cm/s or E0\A0 (pseudonormalization)
E/A [ 2.0 and DT \ 150 ms, E0\ A0 (restriction)
(d) Left atrial volume index [ 40 ml/m2.
Systolic LV dysfunction was diagnosed when the LVEF
was \50 % in echocardiography.
Table 2 Characteristics of type 1 diabetic subjects with hypertension
(subgroup B) who completed the study, at baseline and at the 7 year
of the follow-up period
Parameter Type 1 diabetes p value
Baseline At the 7 year of
follow-up
n = 1,199 n = 1,199
Sex/male n (%) 605 (50.5) 605 (50.5) 1.00
Age* (years) 57.7 ± 4.3 64.7 ± 4.3 0.40
BMI* (kg/m2) 25.2 ± 3.1 27.1 ± 2.6 0.05
HbA1c (%) 8.5 ± 1.4 8.4 ± 1.3 0.65
Diabetes duration*
(years)
38.4 ± 15.2 45.4 ± 15.2 0.30
Any diabetic
retinopathy n (%)
959 (80) 963 (80.3) 0.86
Sensorimotor
neuropathy n (%)
72 (6) 84 (7) 0.85
CAN n (%) 42 (3.5) 44 (3.7) 0.83
GFR* (ml/min/
1.73 m2)
77.0 ± 15.1 70.1 ± 15.1 0.05
Albuminuria n (%) 88 (7.3) 92 (7.7) 0.76
Systolic BP* (mmHg) 135.5 ± 8.3 129.3 ± 8.9 \0.0001
Diastolic BP*
(mmHg)
87.3 ± 14.4 83.1 ± 13.2 0.008
LDL-ch* (mmol/l) 3.3 ± 0.4 2.8 ± 0.4 0.001
Triacylglycerol *
(mmol/l)
1.3 ± 0.3 0.9 ± 0.2 \0.0001
HDL-ch* (mmol/l) 1.3 ± 0.3 1.4 ± 0.3 0.09
ACE-i n (%) 1,005 (83.8) 1,010 (84.2) 0.78
ARA n (%) 90 (7.5) 85 (7.1) 0.69
Ca-blocker n (%) 715 (59.6) 890 (74.2) \0.0001
b-blocker n (%) 428 (35.7) 433 (36.1) 0.83
Aspirin n (%) 1,180 (98.4) 1,189 (99.2) 0.09
Statin n (%) 1,100 (91.7) 1,190 (99.2) \0.0001
Fibrate n (%) 23 (1.9) 24 (2.0) 0.88
Diuretic n (%) 252 (21.0) 261 (21.8) 0.65
ARA angiotensin receptor antagonist, Ca-blocker calcium channel
blocker, CAN cardiac autonomic neuropathy, BP blood pressure, GFR
glomerular filtration rate
* Mean values ± SD
Table 1 Characteristics for the subjects without hypertension and
without coronary disease (subgroup A) who completed the study, at
baseline and at the 7 year of follow-up
Parameter Type 1 diabetes p value
Baseline At the 7 year of
follow-up
n = 393 n = 390
Sex/male n (%) 194 (49.4) 191 (49.0) 0.91
Age* (years) 34.8 ± 7.9 41.8 ± 7.9 0.45
BMI* (kg/m2) 25.4 ± 2.3 26.2 ± 2.5 0.05
HbA1c* (%) 7.8 ± 1.4 7.4 ± 1.3 0.05
Diabetes duration*
(years)
26.4 ± 5.6 33.4 ± 5.6 0.32
Any diabetic
retinopathy n (%)
106 (27) 109 (28) 0.90
CAN n (%) 4 (1.0) 5 (1.3) 0.99
GFR* (ml/min/
1.73 m2)
110.0 ± 3.5 112.0 ± 3.4 0.09
Systolic BP*
(mmHg)
125.2 ± 12.6 127.2 ± 11.8 0.07
Diastolic BP*
(mmHg)
74.3 ± 11.5 75.4 ± 12.2 0.08
LDL-ch* (mmol/l) 3.1 ± 1.2 3.0 ± 0.8 0.05
Triacylglycerol*
(mmol/l)
1.1 ± 0.5 1.0 ± 0.5 0.17
HDL-ch* (mmol/l) 1.4 ± 0.4 1.5 ± 0.3 0.65
Statin therapy n (%) 158 (40.2) 217 (55.6) \0.0001
CAN cardiac autonomic neuropathy, BP blood pressure, GFR glo-
merular filtration rate
* Mean values ± SD
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Exercise treadmill test, perfusion scintigraphy
The remaining 1,727 subjects underwent an exercise
treadmill test (ETT) or perfusion scintigraphy (when ETT
was contraindicated or inconclusive) to exclude CHD.
Then, coronary angiography was performed in 102 patients
with the positive results of ETT or scintigraphy. Significant
CHD was diagnosed if the luminal diameter of the vessel
was reduced by C50 %.
Study subgroups
After baseline assessment, the study cohort was divided
into three subgroups (A, B, and C) to evaluate the effect of
diabetes on cardiac function in patients without hyperten-
sion and CHD (subgroup A), in patients with concomitant
hypertension (subgroup B), and in those with significant
CHD (subgroup C) (Fig. 1).
All patients with significant CHD had concomitant
hypertension.
Follow-up
Study subjects were followed up for 7 years. All diagnostic
procedures were repeated at 7 years or earlier if necessary.
During the follow-up, coronary angiography was per-
formed in 26 patients (3 new cases of stable CHD with
positive ETT; recurrent stable angina in 15 patients with
previously diagnosed CHD; acute coronary syndromes in 8
patients with previously diagnosed CHD).
All participants were treated in compliance with the
current guidelines on cardiac and diabetes care.
A total of 42 patients were lost to follow-up:
1. Patients unable to keep appointments (n = 33; without
MD and HF). There were no significant clinical
differences in demographic parameters, NT-proBNP
levels, and the results of echocardiography between
patients who dropped out from the study and those
who completed the study (data not shown).
2. Deaths during the study (all patients without MD and
HF before death): hypoglycaemia (n = 2), pulmonary
embolism (n = 2), unknown aetiology of sudden death
(n = 1), stroke (n = 2), cancer (n = 2).
At 7 years, there were 3 new cases of hypertension
diagnosed in subgroup A. These participants were subse-
quently moved to subgroup B. At 7 years, there were also 3
new cases of significant CHD diagnosed in subgroup B.
These participants were subsequently moved to subgroup C.
A total of 1,685 subjects with type 1 diabetes completed
the study (men, 50.6 %; baseline mean age, 51.2 ±
10.3 years; mean HbA1c, 8.2 ± 1.2 %). Only patients who
fully complied with the protocol were included in the final
analysis. The number of subjects in particular subgroups
who completed the study was as follows:
• subgroup A: baseline—393, at 7 years—390
• subgroup B: baseline—1,199, at 7 years—1,199
Table 3 Characteristics of type 1 diabetic subjects with hypertension
and CHD (subgroup C) who completed the study, at baseline and at
the 7 year of follow-up period
Parameter Type 1 diabetes p value
Baseline At the 7 year of
follow-up
n = 93 n = 96
Sex/male n (%) 53 (57.0) 56 (58.3) 0.85
Age* (years) 58.7 ± 4.3 65.7 ± 4.3 0.40
BMI* (kg/m2) 25.2 ± 3.1 27.1 ± 2.6 0.05
HbA1c (%) 8.5 ± 1.4 8.4 ± 1.3 0.65
Diabetes duration*
(years)
38.4 ± 15.2 45.4 ± 15.2 0.30
Any diabetic
retinopathy n (%)
93 (100) 96 (100) 1
Sensorimotor
neuropathy n (%)
9 (10) 12 (12) 0.88
CAN n (%) 40 (43.0) 43 (44.8) 0.81
GFR* (ml/min/
1.73 m2)
77.0 ± 15.1 70.1 ± 15.1 0.06
Albuminuria n (%) 85 (91.4) 90 (93.8) 0.54
Systolic BP*
(mmHg)
135.5 ± 8.3 129.3 ± 8.9 \0.0001
Diastolic BP*
(mmHg)
87.3 ± 14.4 83.1 ± 13.2 0.008
LDL-ch* (mmol/l) 3.3 ± 0.4 2.8 ± 0.4 0.001
Triacylglycerol *
(mmol/l)
1.3 ± 0.3 0.9 ± 0.2 \0.00001
HDL-ch* (mmol/l) 1.3 ± 0.3 1.4 ± 0.3 0.09
Previous MI n (%) 17 (18.3) 25 (26.0) 0.20
Revascularization
n (%)
40 (43.0) 58 (60.4) 0.017
ACE-i n (%) 82 (88.2) 82 (85.4) 0.58
ARA n (%) 8 (8.6) 11(11.5) 0.51
Ca-blocker n (%) 82 (88.2) 80 (83.3) 0.34
b-blocker n (%) 86 (92.5) 86 (89.6) 0.49
Aspirin n (%) 93 (100.0) 96 (100.0) 1.00
Statin n (%) 93 (100.0) 96 (100.0) 1.00
Fibrate n (%) 6 (6.5) 5 (5.2) 0.96
Diuretic n (%) 35 (37.6) 55 (57.3) 0.007
Nitrate n (%) 80 (86.0) 82 (85.4) 0.91
Aldosterone
antagonist n (%)
2 (2.2) 3 (3.1) 0.97
ARA angiotensin receptor antagonist, Ca-blocker calcium channel
blocker, CAN cardiac autonomic neuropathy, MI myocardial infarc-
tion, GFR glomerular filtration rate, BMI body mass index
* Mean values ± SD
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• subgroup C: baseline—93, at 7 years—96
All participants gave their written informed consent. The
study was approved by the Ethical Review Committee and
the study protocol complied with the Helsinki Declaration.
Study end-points
The primary end-point was the prevalence and incidence of
MD and HF in the study population. The secondary end-
point were NT-proBNP levels. The outcomes were evalu-
ated independently by an adjudication committee consisting
of experienced cardiologists. The committee was blinded to
concomitant disorders (hypertension, CHD) and metabolic
control in the study population.
Statistical analysis
Statistical analysis was performed using the STATISTICA
7.0 PL software. All continuous variables were expressed
as mean ± standard deviation, and categorical variables
were expressed as percentages.
The Mann–Whitney U test was used to compare nor-
mally and non-normally distributed continuous variables.
The analysis of variance (ANOVA) or the Kruskal–Wallis
test were applied where appropriate.
The v2 test was used to evaluate the differences in cat-
egorical variables between the subgroups. All statistical
tests were two-sided. The relationships between continuous
variables were assessed by the Spearman’s rank correlation.
Fig. 1 Flow diagram describing the cohort changes from enrolment to study completion
Acta Diabetol (2013) 50:597–606 601
123
A multiple regression analysis was used for baseline esti-
mation of the predictors of HF prevalence, due to the small
incidence of new HF cases during the 7-year follow-up (5
persons). Statistical significance was accepted at p \ 0.05.
Prevalence was defined as the total number of HF cases
at baseline and at 7 years, calculated per 1,000 subjects.
Incidence was defined as the number of new HF cases in
the study population per year over the 7-year follow-up
period, calculated per 1,000 subjects.
Results
The characteristics of the subgroups are summarized in
Tables 1, 2, 3. All patients were treated with the model of
multiple (4 or more) insulin injections.
Echocardiography and serum NT-proBNP levels
Patients in subgroup A (no hypertension or CHD) had
normal echocardiographic parameters and NT-proBNP
levels. At baseline and at 7 years, MD was observed only
in patients with hypertension and CHD (subgroups B and
C).
Diastolic dysfunction was the most common abnormal-
ity and was observed in 15.6 % of the patients with
hypertension and CHD.
The prevalence of MD (both systolic and diastolic
manifestations) in the entire group was 14.5 %, and the
incidence at 7 years was 0.01 % per year. During the
7-year follow-up, 3 new cases of MD were diagnosed.
The results of echocardiography and NT-proBNP levels
at baseline and at 7 years are summarized in Table 4.
Chronic heart failure
At the end of the follow-up, the prevalence of HF (both
HFPEF and HFREF) was 3.7 % and the incidence was
0.02 % per year (only subgroups B and C).
At baseline, patients with HFPEF constituted 85 % of
the HF population, while those with HFREF the remaining
15 %. During the follow-up, 1 new case of HFPEF and 4
new cases of HFREF were diagnosed.
The baseline predictors of prevalent HF are summarized
in Table 5. Cardiac autonomic neuropathy, sensorimotor
neuropathy, and any diabetic retinopathy were not found to
be independent predictors of HF in a multivariate logistic
regression analysis.
Mean HbA1c in patients with HF was 8.6 ± 1.4 %.
At baseline, 78.5 % of the patients with HF were in the
NYHA Class II and 21.5 % in the NYHA Class III. All
patients with Class III were in subgroup C.
During the follow-up, none of the subjects died of HF,
although transient exacerbation of symptoms (not requiring
immediate hospitalization) was observed in 9.1 % of these
patients.
Discussion
Our study showed that patients with type 1 diabetes with-
out any cardiovascular disorders have no evidence of MD
and HF. MD and HF were observed only when diabetes
coexisted with hypertension and significant CHD.
In the entire study group, the prevalence and incidence
of both MD and HF were relatively low, although they
were more common in patients with CHD compared with
hypertensive subjects. Additionally, serum NT-proBNP
levels were significantly higher in subjects with CHD
compared with those who had only hypertension. This
suggests a more advanced progression of HF due to myo-
cardial ischaemia.
HFPEF was the most frequent manifestation of HF. No
significant differences between sexes were observed.
To the best of our knowledge, the current study has been
the first to report the prevalence and incidence of MD and
HF in patients with type 1 diabetes. Similar studies, but
focused on patients with type 2 diabetes, have already been
published and attracted wide readership [1, 4, 6–10].
Numerous experimental studies describing the effect of
acute hyperglycaemia (due to absolute insulin deficiency)
on the development of myocardial damage suggested that
elevated glucose levels may affect cardiac function
[15–20]. However, the prevalence and incidence of MD
and HF in our study cohort appear to be lower than
expected. There are several possible explanations. First, all
study subjects were on intensive insulin therapy, and con-
comitant treatment with statins, antihypertensive drugs,
aspirin, and other medications was common. Second, gly-
caemic control, while not meeting the goals as defined by
the Polish Diabetes Association (HbA1c \ 6.5 %) and the
American Diabetes Association (HbA1c \ 7.0 %), was still
satisfactory and similar to that reported in the EDIC study
[21, 22]. Moreover, the study population was relatively
young. Finally, in type 1 diabetes, other atherosclerotic risk
factors including obesity, lipid abnormalities, or hyper-
tension are less prevalent than in type 2 diabetes.
Although many investigators demonstrated some dif-
ferences in the parameters of diastolic function and NT-
proBNP levels between small groups of patients with type
1 diabetes without cardiovascular disorders and non-
diabetic controls, none of them reported the prevalence and
incidence rates of MD and HF [23–28]. Our study, simi-
larly to some others, focused on normal diastolic function
in type 1 diabetic patients [29, 30].
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The most common abnormality in our study was diastolic
manifestation of MD. It was observed at baseline in 15.6 %
of hypertensive and coronary patients without HF. Zanchetti
et al. reported that in the population diastolic dysfunction
was observed in 26–46 % of elderly, hypertensive patients
without HF (C65 years) [31]. In our study, patients with
hypertension and CHD were younger (mean baseline age,
57 years). Meanwhile, an early diagnosis of MD and treat-
ment of predisposing disorders such as hypertension and
CHD could potentially delay the onset of HF.
Several epidemiological studies have recently reported
that HFPEF is observed in 50 % of the patients with HF,
and the outcomes are similar to those seen in HFREF [14].
In our study, baseline HFPEF was observed in 85 % of the
patients with HF and HFREF was observed in the
remaining 15 %, due to the relatively low incidence of
systolic dysfunction in coronary patients.
Interestingly, Lind et al. have recently published the
results of their study in a large cohort of type 1 diabetic
patients from the national Swedish diabetes registry. The
authors reported an association between glycaemic control
and the prevalence of HF [32]. They diagnosed HF mainly
on the basis of clinical symptoms, while we also performed
echocardiography and measured NT-proBNP levels.
Additionally, we investigated MD and systolic and dia-
stolic manifestations of HF.
Lind et al. considered all possible causes of HF including
those observed in the general population (e.g. valvular dis-
eases, atrial fibrillation). In contrast, we assessed the actual
effect of diabetes alone or with hypertension and CHD on the
prevalence and incidence of HF in type 1 diabetic patients.
For this reason, the overall number of HF cases in the study
by Lind et al. might be higher than in our study.
Similarly to Lind et al., we demonstrated that age, sys-
tolic blood pressure, CHD, duration of diabetes, and
myocardial infarction were independent HF predictors. In
the Swedish study, the incidence of HF was increased both
in the lowest (\6.5 %) and highest (C10.5 %) HbA1c
thresholds. In our study, HbA1c level (mean value in HF
patients, 8.6 %) was also an independent predictor of
prevalent HF [32].
In a meta-analysis of randomised trials of intensive
glycaemic control in patients with type 2 diabetes, inten-
sive glycaemic therapy had no preventive effect on HF
[33].
In contrast to the study by Lind et al., we did not observe
that body mass index or smoking was independent pre-
dictors of HF in type 1 diabetes. Moreover, subjects with
atrial fibrillation were excluded from our study (due to
difficulties in assessing diastolic dysfunction). Further-
more, we determined that decreased glomerular filtration
rate was an independent HF predictor. This particular
Table 5 Baseline predictors of prevalent heart failure in type 1 diabetic patients
Predictor Women Men
OR 95 % CI p value OR 95 % CI p value
Univariate analysis
Age (per year) 1.12 1.04–1.20 0.003 1.06 1.01–1.12 0.015
GFR \ 60 ml/min/1.73 m2 3.17 1.41–7.11 0.005 7.06 3.19–15.59 0.000001
Significant CHD 2.88 1.14–7.48 0.04 3.40 1.37–8.41 0.008
Any diabetic retinopathy 12.34 1.65–92.12 0.01 2.49 1.01–6.28 0.005
Diabetes duration (per year) 1.07 1.04–1.11 0.0001 1.08 1.04–1.12 0.0001
Systolic BP [ 140 mmHg 2.31 1.01–5.69 0.005 4.48 1.52–13.15 0.006
Diastolic BP [ 90 mmHg 3.66 1.57–8.23 0.029 – – –
HbA1c (%) 1.61 1.25–2.07 0.0002 1.45 1.14–1.85 0.003
Triacylglycerol (mmol/l) 3.13 1.30–7.63 0.011 – – –
Albuminuria – – – 4.94 2.23–10.96 0.00009
Multivariate analysis
Age (per year) 1.05 1.01–1.14 0.04 1.01 1.01–1.08 0.04
Diabetes duration (per year) 1.06 1.02–1.11 0.006 1.06 1.02–1.11 0.006
Significant CHD 2.50 1.01–7.56 0.04 3.04 1.13–8.20 0.02
GFR \ 60 ml/min/1.73 m2 1.56 1.11–2.89 0.04 0.95 0.93–0.97 \0.0001
Systolic BP [ 140 mmHg 2.22 1.01–5.87 0.007 2.01 1.11–3.63 0.01
HbA1c (%) 1.77 1.30–2.41 0.0003 1.39 1.01–1.89 0.04
p Value for model \ 0.0001; v2 = 38.47 p Value for model \ 0.0001; v2 = 42.41
BP blood pressure, GFR glomerular filtration rate, HbA1c glycosylated haemoglobin
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finding was corroborated by other investigators who stud-
ied the general population [34].
The results of our study suggest that moderate hyper-
glycaemia alone does not exert a substantial adverse effect
on myocardial function in type 1 diabetic patients without
concomitant cardiovascular disorders. In type 1 diabetic
patients with hypertension and CHD, the incidence of HF
may be similar to that in the general population matched
for age. Therefore, it seems quite likely that current phar-
macotherapy targeting concomitant cardiovascular disor-
ders exerts a cardioprotective effect by reducing the overall
risk of cardiac complications.
Considering the high relative risk of major health burden
associated with HF, it is important to investigate the
potentially modifiable factors in the development of HF in
type 1 diabetes.
The following study limitations should be considered.
First, it was a large, prospective study that reflected a
consecutive case series ascertained by the authors between
1999 and 2004. Because of the observational study design,
it is impossible to draw any conclusion about the efficacy
and safety of various types of modern therapy and their
potential for preventing MD and HF in patients with type 1
diabetes. Moreover, not all age ranges were covered (the
youngest patient at baseline was 20-year-old and the oldest
was 65). Finally, there is no registry of HF patients in
Poland so the actual number of patients with type 1 dia-
betes and concomitant HF may be underestimated.
In summary, in our patients with type 1 diabetes, MD
and HF occurred only when diabetes coexisted with car-
diovascular disorders affecting myocardial function. The
prevalence and incidence of HF in diabetic subjects with
hypertension and CHD were relatively low. While the
cause of this observation remains uncertain, it could
probably be explained, at least partially, by the cardio-
protective effect of concomitant treatment.
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